ArticleAging2015
Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus).
Article in Aging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Part I: Short Term ApoE-dependent Cerebral Blood Flow Response to Sirolimus in Cognitively Normal Adults Part II: Short Term ApoE-dependent Cerebral Blood Flow and Lung Perfusion Response to Sirolimus in Cognitively Normal Adults
Effects of Sirolimus on Middle Aged Asymptomatic ApoE4 Carriers
Who cites it
38 citing papers in PubMed, 49 citations in OpenAlex.
- A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects.Experimental gerontology · 2018Trial
- A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs.GeroScience · 2017Trial
- Review
- Modelling the ageing dependence of cancer evolutionary trajectories.Nature reviews. Cancer · 2025Review
- Inhibition of mTORC1 by rapamycin results in feedback activation of AktbioRxiv : the preprint server for biology · 2025Article
- A pilot study evaluating dosing tolerability of 17α-estradiol in male common marmosets (Callithrix jacchus).GeroScience · 2025Article
- Comparative acute toxicity of intravenous paclitaxel and sirolimus in rats.Current research in toxicology · 2025Article
- Senotherapeutic Peptide 14 Suppresses Th1 and M1 Human T Cell and Monocyte Subsets In Vitro.Cells · 2024Article
- Age-related changes in hematological biomarkers in common marmosets.American journal of primatology · 2024Article
- Toxicology of pharmaceutical and nutritional longevity compounds.Expert reviews in molecular medicine · 2023Review
- Therapeutic Antiaging Strategies.Biomedicines · 2022Review
- Making sense of the ageing methylome.Nature reviews. Genetics · 2022Review
- Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice.Aging cell · 2022Article
- Clinically available immunosuppression averts rejection but not systemic inflammation after porcine islet xenotransplant in cynomolgus macaques.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022Article
- From mutation to mechanism: deciphering the molecular function of genetic variants linked to human ageing.Briefings in functional genomics · 2022Article
- Control of aging by the renin-angiotensin system: a review ofFrontiers in pharmacology · 2022Review
- Effect of rapamycin on aging and age-related diseases-past and future.GeroScience · 2021Review
- Alternative Animal Models of Aging Research.Frontiers in molecular biosciences · 2021Review
- The quest to slow ageing through drug discovery.Nature reviews. Drug discovery · 2020Review
- The mystery of the ketogenic diet: benevolent pseudo-diabetes.Cell cycle (Georgetown, Tex.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
Rapamycin has been shown to extend lifespan in rodent models, but the effects on metabolic health and function have been widely debated in both clinical and translational trials. Prior to rapamycin being used as a treatment to extend both lifespan and healthspan in the human population, it is vital to assess the side effects of the treatment on metabolic pathways in animal model systems, including a closely related non-human primate model. In this study, we found that long-term treatment of marmoset monkeys with orally-administered encapsulated rapamycin resulted in no overall effects on body weight and only a small decrease in fat mass over the first few months of treatment. Rapamycin treated subjects showed no overall changes in daily activity counts, blood lipids, or significant changes in glucose metabolism including oral glucose tolerance. Adipose tissue displayed no differences in gene expression of metabolic markers following treatment, while liver tissue exhibited suppressed G6Pase activity with increased PCK and GPI activity. Overall, the marmosets revealed only minor metabolic consequences of chronic treatment with rapamycin and this adds to the growing body of literature that suggests that chronic and/or intermittent rapamycin treatment results in improved health span and metabolic functioning. The marmosets offer an interesting alternative animal model for future intervention testing and translational modeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.